| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/14/2005 | CA2470908A1 Therapy for cancer |
| 04/13/2005 | EP1522591A2 Transgenically produced non-secreted proteins |
| 04/13/2005 | EP1522590A1 Methods for producing modified glycoproteins |
| 04/13/2005 | EP1522584A2 Phosphatidylinositol 3-kinase p110 delta catalytic subunit |
| 04/13/2005 | EP1522583A2 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sina) |
| 04/13/2005 | EP1522312A1 Biologically stable liquid composition of FVIII, of vWF or of FVIII/vWF complex of human origin. |
| 04/13/2005 | EP1522311A1 Use of somatostatin or analogs thereof for the preparation of a medicament for the regulation of ovarian follicles reserve by non menopausaled women |
| 04/13/2005 | EP1521832A2 Genes |
| 04/13/2005 | EP1521824A2 Nucleic acid-associated proteins |
| 04/13/2005 | EP1521822A2 Protein modification and maintenance molecules |
| 04/13/2005 | EP1521779A1 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same |
| 04/13/2005 | EP1521773A1 Phosphoinositolglycan (pig)-binding protein from adipocytes |
| 04/13/2005 | EP1521772A1 Mutant proteins and use thereof for the manufacture of medicaments and the treatment of humans or animals suffering from conformational diseases |
| 04/13/2005 | EP1521770A1 Method for the production of protamine |
| 04/13/2005 | EP1521769A2 Tubulysin conjugates |
| 04/13/2005 | EP1521768A2 RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 04/13/2005 | EP1521754A2 Viral inhibitors |
| 04/13/2005 | EP1521735A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 04/13/2005 | EP1521597A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 04/13/2005 | EP1521596A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 04/13/2005 | EP1521594A2 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 04/13/2005 | EP1521593A2 Transdermal botulinum toxin compositions |
| 04/13/2005 | EP1521591A1 Use of pthrp antagonists for treating renal cell carcinoma |
| 04/13/2005 | EP1521590A1 Novel medicament combinations based on magnesium salts and fibrinolytics |
| 04/13/2005 | EP1521589A2 Bioactivation of particles |
| 04/13/2005 | EP1521588A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 04/13/2005 | EP1521587A2 Gp41 peptides and methods based-thereon for inhibiting hiv fusion to target cells |
| 04/13/2005 | EP1521523A2 Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
| 04/13/2005 | EP1465912A4 Novel chimeric tnf ligands |
| 04/13/2005 | EP1353698A4 Recombinant serum albumin for use in cleansing or dermatological products for skin or hair |
| 04/13/2005 | EP1335706B1 Process fo r the production of microspheres of pancreatic enzymes with high stability |
| 04/13/2005 | EP1317484B1 Variants of the phleum pratense phl p 1 allergenic protein |
| 04/13/2005 | EP1303296B1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof |
| 04/13/2005 | EP1268498B1 Cardioprotective phosphonates |
| 04/13/2005 | EP1259535B1 Cyclic hexapeptide derivatives |
| 04/13/2005 | EP1183353B1 Modified chimeric polypeptides with improved pharmacokinetic properties |
| 04/13/2005 | EP1115409A4 Composition for extending post meal satiety |
| 04/13/2005 | EP1073453B1 Use of angiotensin analogs for the manufacture of a medicament for increasing white blood cell survival and mobilizing haematopoietic progenitor cells following chemotherapy |
| 04/13/2005 | EP0930893B1 Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| 04/13/2005 | EP0774971B1 Synthetic peptide inhibitors of hiv transmission |
| 04/13/2005 | EP0728210B1 Thrombin mutants |
| 04/13/2005 | CN1606620A Slow releasing protein polymer |
| 04/13/2005 | CN1606568A Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor |
| 04/13/2005 | CN1606567A Antimicrobial polypeptides from pseudoplectania nigrella |
| 04/13/2005 | CN1606457A Methods for sterilizing preparations containing albumin |
| 04/13/2005 | CN1606456A Restricted expression lentiviral vectors |
| 04/13/2005 | CN1606452A Liquid composition of modified factor vii polypeptides |
| 04/13/2005 | CN1606451A Remedies and/or preventives for conformational diseases |
| 04/13/2005 | CN1606450A Polypeptide, the conjugate thereof with doxorubicin and a pharmaceutical composition based thereon |
| 04/13/2005 | CN1606449A Improved use of antitumoral compound in cancer therapy |
| 04/13/2005 | CN1606448A Composition for the treatment of lupus |
| 04/13/2005 | CN1606447A Storage-stable fibrinogen solutions |
| 04/13/2005 | CN1606443A Substituted diketopiperazines as oxytocin antagonists |
| 04/13/2005 | CN1606432A Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 04/13/2005 | CN1605592A Protease resistant mutein of human ciliary neurotrophic factor and its preparation and use |
| 04/13/2005 | CN1605590A 10 peptide with cell protection function |
| 04/13/2005 | CN1605346A Vacuum-electrolysis and flocculation reclaiming technology for preparing |
| 04/13/2005 | CN1196797C Diagnostics and therapeutics for glaucoma |
| 04/13/2005 | CN1196794C Antiseptic WAP-8294A and WAP-8294AX and their prepn process and antiseptic composition |
| 04/13/2005 | CN1196791C Psudomonas exotoxin-myelin basic protein chimeric proteins |
| 04/13/2005 | CN1196787C Virulence genes and proteins and their use |
| 04/13/2005 | CN1196786C Methods for preventing graft rejection in transplantation and for producing universal gene therapy host cell |
| 04/13/2005 | CN1196785C Beta-amyloid peptdie-binding proteins and polynucleotides encoding the same |
| 04/13/2005 | CN1196784C Promoter of human endoglin gene and its use |
| 04/13/2005 | CN1196711C Chromatographic process for obtaining very pure cycloporin A and related cyclosporins |
| 04/13/2005 | CN1196495C Mutant human CD80 and compositions and methods of making and using the same |
| 04/13/2005 | CN1196488C Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 04/12/2005 | US6878817 Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 04/12/2005 | US6878813 Elastase-resistant antithrombin III (ATIII) for treating blood clotting disorders |
| 04/12/2005 | US6878812 Nucleotide sequences coding enzymatic polypeptide for use in treatment of inflammation and cancer |
| 04/12/2005 | US6878810 Zace1: a human metalloenzyme |
| 04/12/2005 | US6878806 Human secreted protein HTEEB42 |
| 04/12/2005 | US6878722 Substituted cycloalkyl P1′ hepatitis C virus inhibitors |
| 04/12/2005 | US6878692 Nucleotide sequences coding apoptosis protein for use in the treatment of autoimmune diseases and cancer |
| 04/12/2005 | US6878689 Administering D-alanyl-3-(naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide and/or salts, especially the dihydrochloride |
| 04/12/2005 | US6878688 Method of treatment of malignant neoplasms and complex preparation having antineoplastic activity for use in such treatment |
| 04/12/2005 | US6878687 Activates the interferon-sensitive responsive promoter element. |
| 04/12/2005 | US6878686 Cross-linked glycopeptide-cephalosporin antibiotics |
| 04/12/2005 | US6878685 Purified Tat and Nef to promote localized accumulation of CD4+ cells, and an antimicrobial chemotherapeutic agent, such as an antibiotic; may also contain tumor necrosis factor-alpha |
| 04/12/2005 | US6878547 Antisense oligonucleotides against tenascin for treating vitiligo |
| 04/12/2005 | US6878542 Using fluorescence-activated cell sorting to separate and recover mammlian progenitor cells |
| 04/12/2005 | US6878529 Compounds for the treatment of sexual dysfunction |
| 04/12/2005 | US6878525 Peptide leukotriene receptor |
| 04/12/2005 | US6878521 Fibril-blocking peptide, a method for preventing fibril formation |
| 04/12/2005 | US6878376 Modulate immunology response |
| 04/12/2005 | US6878375 HA-1 antigen |
| 04/12/2005 | US6878371 Isolating autologous bone marrow- mononuclear cells from the subject; and transplanting locally into the tissue an effective amount of the autologous bone-marrow mononuclear cells, resulting in formation of new blood vessels in tissue |
| 04/12/2005 | US6878370 Chemically modified TNF-α |
| 04/12/2005 | US6877514 Organ transplantation; administering a relatively large number of stem cells, combined with the creation of thymic space without the need for whole body irradiation; mixed chimerism can be formed without hematopoietic space-creating irradiation |
| 04/12/2005 | CA2417135C Chimeric pre-activated transcription factors |
| 04/12/2005 | CA2385854C Formulation for menopausal women |
| 04/12/2005 | CA2337745C Human growth hormone aqueous formulation |
| 04/12/2005 | CA2278106C Tissue factor methods and compositions for coagulation and tumor treatment |
| 04/12/2005 | CA2267994C Truncated platelet-activating factor acetylhydrolase |
| 04/12/2005 | CA2252576C Use of dipeptidyl peptidase iv inhibitors for lowering the blood glucose level in mammals |
| 04/12/2005 | CA2250704C Glial cell line-derived neurotrophic factor receptor |
| 04/12/2005 | CA2207289C Supplemented and unsupplemented tissue sealants, methods of their production and use |
| 04/12/2005 | CA2203936C Boronic ester and acid compounds, synthesis and uses |
| 04/12/2005 | CA2137961C Cyclic depsipeptides having 18 ring atoms, and their use for combating endoparasites |
| 04/12/2005 | CA2123363C Lysosomal enzyme-cleavable antitumor drug conjugates |